It is thus no surprise that LGR5 has attracted a great deal of therapeutic interest owing to its overexpression in cancers with de-regulated Wnt pathway activity relative to low levels in healthy tissues, and the fact that tumour cells require LGR5 for proliferation. The gene discussed is LGR5; the disease is cancer.